Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-26T13:26:41.342Z Has data issue: false hasContentIssue false

Dopamine Partial Agonist Antipsychotics

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 185 - 199
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Otsuka USA Pharmaceutical Inc. (2017). Abilify Maintena Package Insert. Rockville, Maryland.Google Scholar
Alkermes Inc. (2020). Aristada Package Insert. Wilmington, Ohio.Google Scholar
Otsuka USA Pharmaceutical Inc. (2020). Abilify MyCite Package Insert. Rockville, Maryland.Google Scholar
Otsuka USA Pharmaceutical Inc. (2020). Abilify Package Insert. Rockville, Maryland.Google Scholar
de la Iglesia-Larrad, J. I., Barral, C., Casado-Espada, N. M., et al. (2019). Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: a review of the literature. Psychiatry Res, 284, 112660.CrossRefGoogle ScholarPubMed
Romeo, B., Blecha, L., Locatelli, K., et al. (2018). Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety. J Psychopharmacol, 32, 385–396.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Aripiprazole Protocol. Sacramento, California.Google Scholar
Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342–353.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.CrossRefGoogle ScholarPubMed

References

Otsuka USA Pharmaceutical Inc. (2020). Rexulti Package Insert. Deerfield, Illinois.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Brexpiprazole Protocol. Sacramento, California.Google Scholar
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.CrossRefGoogle ScholarPubMed

References

Allergan USA Inc. (2019). Vraylar Package Insert. Madison, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Ziprasidone Protocol. Sacramento, California.Google Scholar
Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342–353.Google Scholar
Cutler, A. J., Durgam, S., Wang, Y., et al. (2018). Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr, 23, 39–50.CrossRefGoogle ScholarPubMed
Azorin, J. M., Simon, N. (2019). Dopamine receptor partial agonists for the treatment of bipolar disorder. Drugs, 79, 1657–1677.CrossRefGoogle ScholarPubMed
Earley, W., Burgess, M. V., Rekeda, L., et al. (2019). Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry, 176, 439–448.CrossRefGoogle ScholarPubMed
Chakrabarty, T., Keramatian, K., Yatham, L. N. (2020). Treatment of mixed features in bipolar disorder: an updated view. Curr Psychiatry Rep, 22, 15.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×